revuforj
revuforj: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | Approved |
FDA Decisions
Frequently asked questions
Who is developing revuforj?
revuforj is being developed by Syndax Pharmaceuticals Inc.
What is revuforj's latest FDA decision?
The most recent tracked FDA decision for revuforj is Approval for 1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. ( 1 ) the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatmen, dated November 15, 2024.
Get deeper analysis on revuforj
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis